Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05246280 · ClinicalTrials.gov registry record · Phase 3
Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA
A Phase 3 study, sponsored by Navidea Biopharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 169
- Enrollment target
NCT05246280 is a Phase 3 study that was terminated before completion, run by Navidea Biopharmaceuticals. The registered enrollment target is 169 participants.
The verdict
NCT05246280, a Phase 3 study, was terminated before completion, sponsored by Navidea Biopharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 169 participants
- Enrollment target
Study Summary
This study will confirm the ability of Tc 99m tilmanocept imaging to predict clinical response in individuals with RA who are beginning anti-TNFα therapy.
Interventions
- DRUG TC99m-tilmanocept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2022-03-02 |
| Est. Completion | 2024-07-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05246280
The ClinicalTrials.gov registry entry for NCT05246280 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Navidea Biopharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TC99m-tilmanocept is the first listed.
NCT05246280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05246280 about?
NCT05246280 is a clinical study titled "Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA". This study will confirm the ability of Tc 99m tilmanocept imaging to predict clinical response in individuals with RA who are beginning anti-TNFα therapy.
What is the current status of trial NCT05246280?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 169 participants. The study started on 2022-03-02. Estimated completion is 2024-07-09.
What interventions are being tested in trial NCT05246280?
The interventions under investigation include: TC99m-tilmanocept (DRUG).
Who is sponsoring clinical trial NCT05246280?
This trial is sponsored by Navidea Biopharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.